Clinical Trial Update: A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating SHR-1210 in patients with advanced or metastatic non-small cell lung cancer is listed, with current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Bronchogenic
• Carcinoma Non-small-cell Lung
• Lung Disease
• Lung Neoplasms
• Neoplasm Bronchial
• Respiratory Tract Disease
• Respiratory Tract Neoplasms Nec

Drugs mentioned

• SHR-1210 (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: UNKNOWN